Cigna Group (CI) · Health Insurance
Cigna Group Q2 2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Official transcript (PDF) ↗Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Cigna is exiting Individual and Family Plans from January 2027 while Evernorth's specialty business grows on biosimilar and generic adoption and pharmacy benefit margins absorb large client renewals.
Cigna Healthcare grew medical customers to 18.4 million, led by Middle and Select markets, while National Accounts membership declined. Premium increases drove growth in the employer business, which also saw better margins. At Evernorth, specialty volume was strong, helped by higher generic and biosimilar use that lowers costs for clients and patients. Pharmacy customers fell to 118.2 million on expected client transitions and lower health plan membership.
Management is steering toward technology, data and AI to personalize customer experiences, widen access and cut costs, and is trimming the portfolio by leaving Individual and Family Plans on January 1, 2027. The main tension is in pharmacy benefits, where large client contract renewals and customer-focused initiatives are cutting profit even as revenue grows, while pharmacy membership keeps shrinking.
Key numbers
- Total revenues · GAAP
- $71.7 billion
- Shareholders' net income · GAAP
- $1.7 billion
- Diluted EPS · GAAP
- $6.29
- Adjusted income from operations per share · non-GAAP
- $7.78
up 7% from a year ago
compared to $5.71 for second quarter 2025
compared with $7.20 for second quarter 2025
| Segment or metric | Value | Change |
|---|---|---|
| Cigna Healthcare medical care ratio | 84.5% | compared to 83.2% for second quarter 2025 |
Where each number comes from
- Total revenues: “Total revenues for the second quarter 2026 increased 7% to $71.7 billion”
- Shareholders' net income: “Shareholders’ net income for the second quarter 2026 was $1.7 billion, or $6.29 per share”
- Diluted EPS: “Shareholders’ net income for second quarter 2026 was $1.7 billion, or $6.29 per share compared to $1.5 billion, or $5.71 per share, for second quarter 2025”
- Adjusted income from operations per share: “adjusted income from operations1 for second quarter 2026 was $2.1 billion, or $7.78 per share, compared with $1.9 billion, or $7.20 per share, for second quarter 2025”
- Cigna Healthcare medical care ratio: “The Cigna Healthcare MCR4 was 84.5% for second quarter 2026, compared to 83.2% for second quarter 2025”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $71.7B | +6.7% | +4.6% |
| Operating income | $2.7B | +16.0% | +13.5% |
| Net income | $1.7B | +8.4% | +0.4% |
| Diluted EPS | $6.29 | +10.2% | +0.5% |
| Operating margin | 3.7% | +0.3 pts | +0.3 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Adjusted income from operations per share | full year 2026 | at least $30.45 |
| Evernorth adjusted income from operations, pre-tax | full year 2026 | at least $6,900 |
| Cigna Healthcare adjusted income from operations, pre-tax | full year 2026 | at least $4,550 |
| Cigna Healthcare medical care ratio | full year 2026 | 83.7% to 84.7% |
Key takeaways
Cigna will exit Individual and Family Plans
The company announced in April 2026 that it will leave the Individual and Family Plans medical business as of January 1, 2027. This narrows Cigna Healthcare toward employer-focused markets.
Specialty growth is driven by volume and biosimilars
Specialty and Care Services saw strong specialty volume growth and higher generic and biosimilar adoption, which the company says lowers costs for clients and patients. Pre-tax operating income rose 22%.
Pharmacy benefit profits fall on client renewals
Pharmacy Benefit Services pre-tax income fell 27%, reflecting large client contract renewals and customer-focused initiatives, consistent with prior commentary. Revenue still rose 8% on drug mix.
Medical membership grows in Middle and Select
Total medical customers rose 2% since year-end to 18.4 million, with gains in Middle and Select markets partly offset by lower National Accounts membership.
Pharmacy customer base shrinks on client transitions
Pharmacy customers fell 4% since year-end to 118.2 million, reflecting expected client transitions and lower membership from health plan clients. This leaves the company with fewer pharmacy relationships even as it pursues AI-led personalization.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $65.6B * |
| Q1 2025 | $65.5B |
| Q2 2025 | $67.2B |
| Q3 2025 | $69.7B |
| Q4 2025 | $72.5B * |
| Q1 2026 | $68.5B |
| Q2 2026 | $71.7B |
| Q3 2026 | $73.7B |
Data
| Q1 2025 | $4.85 |
| Q2 2025 | $5.71 |
| Q3 2025 | $6.98 |
| Q1 2026 | $6.26 |
| Q2 2026 | $6.29 |
| Q3 2026 | $5.47 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 3.3% |
| Q1 2025 | 3.0% |
| Q2 2025 | 3.4% |
| Q3 2025 | 3.7% |
| Q4 2025 | 3.2% |
| Q1 2026 | 3.4% |
| Q2 2026 | 3.7% |
| Q3 2026 | 3.3% |
Questions
What is Cigna doing with its Individual and Family Plans business?
Cigna announced in April 2026 that it plans to exit the Individual and Family Plans medical business as of January 1, 2027.
Why did pharmacy benefit profit fall?
Pharmacy Benefit Services pre-tax income fell 27% because of client-focused initiatives, including large client contract renewals, and customer-focused initiatives, consistent with prior commentary.
What is driving growth in Cigna's specialty business?
Strong specialty volume growth and organic growth in specialty businesses, including higher generic and biosimilar adoption, drove the segment's results.
How did Cigna's customer base change this quarter?
Medical customers rose 2% since December 31, 2025 to 18.4 million on Middle and Select market growth, while pharmacy customers fell 4% to 118.2 million.
Where is Cigna focusing its strategy?
Management said it is using technology, data and AI to deliver more personalized experiences, improve access and lower costs.
Documents
From Cigna Group investor relations
SEC filing